Table 2.
Substance | Study | Substance use | Total sample size | Prevalence | Pooled effect (95%CI) | τ | Notes |
---|---|---|---|---|---|---|---|
Cocaine | (Ko et al., 2012) | 12 | 1645 | 0.01 (0.00, 0.01) | 0.01 (0.00, 0.03) | 0.01 | In the past 6 months |
(Lim et al., 2015) | 15 | 1235 | 0.01 (0.01, 0.02) | In the past 6 months | |||
(Sapsirisavat et al., 2016) | 3 | 499 | 0.01 (0.00, 0.01) | Categorised to rare/regular | |||
(Sze et al., 2020) | 29 | 569 | 0.05 (0.03, 0.07) | In the past 6 months | |||
(Z. Wang et al., 2020) | 0 | 88 | 0.01 (0.00, 0.01) | In the past year | |||
(Yang et al., 2016) | 1 | 205 | 0.00 (0.00, 0.01) | MSMLHIV | |||
| |||||||
GHB/GBL | (Ko et al., 2012) | 33 | 1645 | 0.02 (0.01, 0.03) | 0.15 (0.03, 0.27) | 0.15 | In the past 6 months |
(Lim et al., 2015) | 34 | 1235 | 0.03 (0.02,0.04) | In the past 6 months | |||
(Sze et al., 2020) | 200 | 569 | 0.35 (0.31, 0.39) | In the past 6 months | |||
(Tan et al., 2021) | 27 | 570 | 0.05 (0.03, 0.06) | - | |||
(Z. Wang et al., 2020) | 29 | 88 | 0.33 (0.23, 0.43) | in the past year | |||
(Wu et al., 2019) | 10 | 79 | 0.13 (0.05, 0.20) | MSMLHIV | |||
| |||||||
Ketamine | (Ko et al., 2012) | 204 | 1645 | 0.12 (0.11, 0.14) | 0.08 (0.04,0.12) | 0.05 | In the past 6 months |
(Lim et al., 2015) | 76 | 1235 | 0.06 (0.05, 0.07) | In the past 6 months | |||
(Nemoto et al., 2012) | 22 | 112 | 0.20 (0.12, 0.27) | Kathoey | |||
(Sze et al., 2020) | 63 | 569 | 0.11 (0.08, 0.14) | In the past 6 months | |||
(N. T. Vu et al., 2017) | 8 | 622 | 0.01 (0.00, 0.02) | - | |||
(Z. Wang et al., 2020) | 2 | 88 | 0.02 (−0.01, 0.05) | In the past year | |||
(Wu et al., 2019) | 6 | 79 | 0.08 (0.02, 0.13) | MSMLHIV | |||
(Yang et al., 2016) | 12 | 205 | 0.06 (0.03, 0.09) | MSMLHIV | |||
| |||||||
Methamphet amine | (Duong et al., 2018) | 15 | 45 | 0.33 (0.20, 0.47) | 0.16 (0.09, 0.22) | 0.13 | - |
(Han et al., 2020) | 16 | 48 | 0.33 (0.20, 0.47) | MSMLHIV | |||
(Hidaka et al., 2014) | 211 | 5731 | 0.04 (0.03, 0.04) | - | |||
(Ko et al., 2012) | 25 | 1645 | 0.02 (0.01, 0.02) | In the past 6 months | |||
(Lim et al., 2015) | 87 | 1235 | 0.07 (0.06, 0.08) | In the past 6 months | |||
(Nishijima et al., 2013) | 57 | 973 | 0.06 (0.04, 0.07) | History of illicit drug use among HIV positive samples | |||
(Piyaraj et al., 2018) | 128 | 1372 | 0.09 (0.08, 0.11) | - | |||
(Sapsirisavat et al., 2016) | 18 | 499 | 0.04 (0.02, 0.05) | Categorised to rare/regular | |||
(Sze et al., 2020) | 222 | 569 | 0.39 (0.35, 0.43) | In the past 6 months | |||
(Tan et al., 2021) | 27 | 570 | 0.05 (0.03, 0.06) | - | |||
(N. T. Vu et al., 2017; N. T. T. Vu et al., 2017) | 89 | 622 | 0.14 (0.12, 0.17) | - | |||
(Z. Wang et al., 2020) | 32 | 88 | 0.36 (0.26, 0.46) | In the past year | |||
(Wansom et al., 2020) | 98 | 563 | 0.17 (0.14, 0.21) | MSMLHIV | |||
(Wu et al., 2019) | 21 | 79 | 0.27 (0.17, 0,36) | MSMLHIV | |||
(Yang et al., 2016) | 26 | 205 | 0.13 (0.08, 0.17) | MSMLHIV |
Notes: - refers to information not applicable. 95% CI = 95% confident interval. MSMLHIV = men have sex with men living with HIV. The scale on the effects is prevalence.